Showing results (11-20 of 50) with videos related to
Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|April 16, 2022
Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic modelJing Jing, Yuan Chen, Luna Musib, et al.Journal of Clinical Pharmacology|August 17, 2021
Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic FunctionRucha Sane, Vikram Malhi, Dhruvitkumar S Sutaria, et al.Investigational New Drugs|October 29, 2008
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumorsAxel-R Hanauske, Herlinde Dumez, Martine Piccart, et al.Clinical Pharmacology in Drug Development|July 23, 2020
Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug CharacteristicsSravanthi Cheeti, Yuzhong Deng, Ilsung Chang, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 30, 2025
Real-world application of physiologically based pharmacokinetic models in drug discoveryLaura G A Santos, Swati Jaiswal, Kuan-Fu Chen, et al.Phytotherapy Research : PTR|October 13, 2005
Pharmacokinetics of valerenic acid after administration of valerian in healthy subjectsGail D Anderson, Gary W Elmer, Eric D Kantor, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 20, 2023
Real-world application of PBPK in drug discoveryLaura G A Santos, Swati Jaiswal, Kuan-Fu Chen, et al.Clinical Pharmacology and Therapeutics|July 19, 2023
Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 PhenotypeManting Chiang, Caroline Sychterz, Vidya Perera, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in studyIgnace Vergote, Frederic Amant, Gülten Oskay-Oezcelik, et al.Neuro-Oncology|February 13, 2010
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomasTeri N Kreisl, Svetlana Kotliarova, John A Butman, et al.Pageof 5